Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair

Breast carcinomas commonly carry mutations in the tumor suppressor p53, although therapeutic efforts to target mutant p53 have previously been unfruitful. Here we report a selective combination therapy strategy for treatment of p53 mutant cancers. Genomic data revealed that p53 mutant cancers exhibi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zonneville, Justin, Wang, Moyi, Alruwaili, Mohammed M., Smith, Brandon, Melnick, Megan, Eng, Kevin H., Melendy, Thomas, Park, Ben Ho, Iyer, Renuka, Fountzilas, Christos, Bakin, Andrei V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275734/
https://www.ncbi.nlm.nih.gov/pubmed/34253820
http://dx.doi.org/10.1038/s42003-021-02370-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275734/
https://www.ncbi.nlm.nih.gov/pubmed/34253820
http://dx.doi.org/10.1038/s42003-021-02370-0

Ejemplares similares